MIM
VRDN icon

Monashee Investment Management’s Viridian Therapeutics VRDN Stock Holding History

Monashee Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,267
Closed -$659K – 202
2018
Q1 		$659K Buy
+6,267
New +$681K 0.18% 89

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Monashee Investment Management's VRDN Position: Q2 2018 in Review

Monashee Investment Management sold out of Viridian Therapeutics (VRDN) in Q2 2018, closing a stake of 6,267 shares — an estimated $659K sold.

Monashee Investment Management first reported a position in VRDN in Q1 2018 and held it in 1 quarter. The position peaked at $659K in Q1 2018. 59 funds tracked by Wall St. Rank hold VRDN as of Q2 2018.

  • Monashee Investment Management reported no remaining Viridian Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Monashee Investment Management sold 6,267 Viridian Therapeutics shares in Q2 2018, an estimated $659K.
  • Monashee Investment Management first reported a position in Viridian Therapeutics in Q1 2018 and held it in 1 quarter.
  • Monashee Investment Management's Viridian Therapeutics position peaked at $659K in Q1 2018.
  • 59 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2018.

Based on Monashee Investment Management's 13F filing for Q2 2018, filed 10 Aug 2018.